Full-Time

Field Clinical Representative

Posted on 7/25/2025

Element Science

Element Science

51-200 employees

Wearable defibrillator for sudden cardiac arrest

No salary listed

No H1B Sponsorship

San Francisco, CA, USA

In Person

Category
Medical, Clinical & Veterinary (2)
,
Required Skills
Sales
Salesforce
Marketing
Google Cloud Platform
Requirements
  • 5+ years of clinical work experience and 2+ years of sales or field representative experience in health care.
  • Must have industry experience with durable medical equipment.
  • Strong communication, organization, and writing skills; and exceptional attention to detail.
  • Excellent relationship management skills.
  • Able to troubleshoot and think creatively under pressure.
  • Familiar with software databases such as Electronic Data Capture systems, CRM, MS Office, Salesforce, and Concur.
  • Demonstrated familiarity with sales processes and a track record of consistently achieving objective key results.
  • Must be able to drive long distances within assigned territory.
  • Must have a valid driver’s license and active vehicle insurance policy.
  • Able to travel outside of region as needed, with occasional overnight trips.
  • Must be able to respond to emergent events within a short time frame.
  • Ability to effectively use a mobile phone, PC, keyboard, and mouse.
Responsibilities
  • Train, fit, and register patients with the Jewel P-WCD following the product instructions for use (IFU) and field personnel training guide.
  • Collaborate with regional Sales/Territory Manager, FCR Team Lead, and other regional FCRs to ensure 24/7 patient field support (this includes after hours/weekend coverage).
  • Assist Reimbursement Specialists with obtaining documentation required for insurance approval.
  • Respond to customer needs and complaints with a sense of urgency regarding products and service issues by developing creative and feasible solutions or working with other related personnel to develop optimal solutions (e.g., sales, marketing, clinical operations, customer service, etc.).
  • Work cross functionally and provide regular feedback on product performance issues, user feedback, and opportunities for enhancements to departments such as reimbursement, customer service, engineering, and clinical field operations in support of continuous improvements on product and process development.
  • Support physician intake and onboarding process.
  • Provide in-depth training sessions and in-services to HCPs and staff on the use, application, and benefits of the Jewel P-WCD system.
  • Support Element Science Clinical Trials as needed with site activation, monitoring activities, and patient enrollment visits.
  • Partner with Commercial, Marketing, and Sales to identify and resolve any account barriers for eligible patients and market expansion.
  • Support market share expansion by developing strong and productive professional relationships with existing and new HCPs at assigned accounts.
  • Regularly, timely, and accurately maintain the customer relationship records of interactions, training sessions, and customer feedback.
  • Support patients through the duration of their prescriptions with interim support visits, PA re-fittings, technical product troubleshooting, and retrieving therapy reports as needed.
  • Order, track, and manage Jewel products for commercial and clinical trials.
  • FCR shall collaborate with contractors supporting case coverage within their region as needed.
  • Ensure compliance with ES DME and quality SOPs, HIPAA regulations, local regulations, ICH guidelines, and GCP guidelines.
  • Participate in and/or complete other activities as assigned.
Desired Qualifications
  • Bachelor’s degree in nursing, science or related field; advanced degree is preferred.
  • Cardiovascular training preferred, IBHRE certification, is a plus!

Element Science creates medical devices to prevent sudden cardiac arrest. Its flagship product, Jewel, is a wearable external defibrillator intended to provide around-the-clock protection by monitoring the heart and delivering a life-saving shock when needed. Jewel is not yet commercially available in the U.S. This device works by continuously monitoring cardiac rhythm and, if a dangerous rhythm is detected, delivering a controlled electrical defibrillation; it is designed for use by at-risk individuals under medical guidance. The company differentiates itself by focusing on a wearable, user-friendly defibrillator and by prioritizing workforce diversity, equity, inclusion, and belonging (DEIB), as well as growth through team expansion. Element Science aims to bring Jewel to market, work with healthcare providers and insurers, increase accessibility for patients at risk of sudden cardiac arrest, and grow its market share while reducing deaths from cardiac events.

Company Size

51-200

Company Stage

Series C

Total Funding

$183.1M

Headquarters

San Francisco, California

Founded

2013

Simplify Jobs

Simplify's Take

What believers are saying

  • Appointed Lee Smith Jr. as Head of Commercial for global launch.
  • Named to Fast Company's 2026 Most Innovative Companies list.
  • Early U.S. launch in select states with expansion plans.

What critics are saying

  • ZOLL's LifeVest holds 90% market share blocking reimbursements.
  • Insufficient sales infrastructure delays U.S. ramp-up post-2025 PMA.
  • NHS England denies reimbursement citing ZOLL's cost-effectiveness.

What makes Element Science unique

  • Jewel Patch-WCD uses patch design unlike garment-based WCDs.
  • Received FDA PMA in April 2025 for U.S. commercialization.
  • Earned CE and UKCA Marks for European market entry.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Stock Options

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Unlimited Paid Time Off

Paid Vacation

Paid Holidays

FSA (Flexible Spending Accounts)

HSA (Health Savings Account)

Employee Assistance Program through PEO

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

-3%

2 year growth

1%
Business Wire
Mar 24th, 2026
Element Science named one of the world's most innovative companies by Fast Company

Element Science, a San Francisco-based health technology company, has been named to Fast Company's World's Most Innovative Companies of 2026 list. The company developed the Jewel Patch Wearable Cardioverter Defibrillator, which monitors and protects cardiovascular patients from sudden cardiac arrest. The Jewel Patch-WCD received FDA approval in April 2025 and European CE mark certification in January 2024. The device is water-resistant, discreet and requires no daily maintenance, distinguishing it as the only wearable cardioverter defibrillator that can be worn whilst showering. The product is currently in early commercial launch across select US states, targeting over 500,000 patients in the US and Europe at temporary risk of sudden cardiac arrest. Element Science's investors include Third Rock Ventures, Google Ventures and Deerfield Management.

Valdosta Daily Times
Jul 8th, 2024
Element Science Receives Prestigious International Red Dot Design Award for Innovative Jewel(R) Patch Wearable Cardioverter Defibrillator

Element Science, an innovative health technology company pioneering a digital wearable platform that monitors and protects high-risk cardiovascular patients, announces that its Jewel(R) Wearable Patch Cardioverter Defibrillator (Jewel) has received the prestigious Red Dot Design Award.

Business Wire
May 15th, 2024
Element Science Appoints Lee Smith, Jr. As The Company'S First Head Of Commercial

With nearly 20 years of successful leadership experience in sales strategy, commercial operations, and customer success, Mr. Smith will be instrumental in driving the launch and expansion of Element Science's Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) in globally markets. (Photo: Business Wire)With nearly 20 years of successful leadership experience in sales strategy, commercial operations, and customer success, Mr. Smith will be instrumental in driving the launch and expansion of Element Science's Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) in globally markets. (Photo: Business Wire)SAN FRANCISCO--(BUSINESS WIRE)--Element Science, an innovative health technology company developing a pioneering digital wearable platform for high-risk cardiovascular patients, announced the appointment of Lee Smith Jr. as the company's first Head of Commercial

Business Wire
Jan 25th, 2024
Element Science Receives Ce Mark Ukca Mark For The Jewel® Patch-Wearable Cardioverter Defibrillator

Element Science Receives CE Mark & UKCA Mark for the Jewel® Patch-Wearable Cardioverter Defibrillator First of its kind life-saving technology receives CE Mark and UKCA Mark, paving the way for enhanced protection of patients with elevated risk of sudden cardiac arrest. (Photo: Business Wire)Element Science Receives CE Mark & UKCA Mark for the Jewel® Patch-Wearable Cardioverter Defibrillator First of its kind life-saving technology receives CE Mark and UKCA Mark, paving the way for enhanced protection of patients with elevated risk of sudden cardiac arrest. (Photo: Business Wire)SAN FRANCISCO--(BUSINESS WIRE)--Element Science, an innovative health technology company pioneering a digital wearable platform for high-risk cardiovascular patients, announced that it has received the European Union’s CE mark certification and Great Britain’s UK Conformity Assessed (UKCA) marking for its novel Patch Wearable Cardioverter Defibrillator (P-WCD) from its Notified Body, the BSI Group.The Jewel P-WCD was designed to address limitations with traditional garment-based WCDs. While these garment-based WCDs have demonstrated the ability to treat sudden cardiac arrest (SCA), a leading cause of death in the United States and in Europe, challenges related to patient comfort and compliance have resulted in avoidable deaths and limited their widespread adoption.The effectiveness of the Jewel defibrillator was confirmed in the Jewel EP Lab Study, conducted in Prague, Czech Republic, in which 16 patients experiencing ventricular arrhythmias were successfully converted to a normal heart rhythm after a single therapeutic shock. The Jewel IDE Study, a pivotal study of 305 patients presented at the American Heart Association’s 2023 Annual Scientific Sessions demonstrated significant patient compliance and protected time resulting in a high number of successful patient saves and no deaths or serious adverse events related to the device (www.ElementScience.com/ide-study/ ).Dr. Uday N

Business Wire
Oct 26th, 2022
Element Science Appoints Trish Howell As Chief Operating Officer | Business Wire

SAN FRANCISCO--(BUSINESS WIRE)--Element Science, an innovative health technology company pioneering a digital wearable platform for high-risk cardiovascular patients transitioning from hospital to home, announced that Trish Howell has been appointed as the Company’s new Chief Operating Officer, effective October 17, 2022. “ Ms. Howell is a transformational leader who has excelled in her positions prior to joining Element Science. As an innovative and seasoned executive, she expands the capabilities of our leadership team at an inflection point of our growth. Her experience in building successful commercial operations at medical device companies gives her a critically valuable perspective that will be an indispensable asset as we look forward to commercializing our technology and expanding our pipeline of products,” said Uday N. Kumar, MD, Founder, President and CEO

INACTIVE